New melanoma drug Zelboraf nearly doubles survival in majority of patients
Investigators from Vanderbilt-Ingram Cancer Center (VICC) and 12 other centers in the United States and Australia have found that a new drug for patients with metastatic melanoma nearly doubled median overall survival....
Source: PhysOrg - Wednesday, 22 February
Related articles:
- Less than a day ago
- 1Vote! Anti-inflammatory drugs may improve survival from severe malaria
LabSpaces - Yesterday
- Less than a few days ago
- 1Vote! Drug-vaccine combo better for breast cancer
Futurity.org - 2 days ago
- Less than a week ago
- 7Vote! Phase I clinical trial shows drug shrinks melanoma brain metastases
e! Science News - 5 days ago
- Older News
- 5Vote! Cancer vaccine combination therapy shows survival benefit in breast cancer
- 1Vote! New under the sun: Recurrent genetic mutations in melanoma
- 4Vote! Countering the drug industry's marketing machine
- 5Vote! Mayo Clinic researchers building melanoma vaccine to combat skin cancer
- 5Vote! Researchers building melanoma vaccine to combat skin cancer
- 4Vote! Drug coordination keeps nursing homes safe
- 4Vote! Text messages help HIV patients stick to antiretroviral drug therapy
- 6Vote! Drug regulation follows heart patient deaths
SciDev.Net - Monday, 12 March - 5Vote! Early surgery controls epilepsy’s seizures
- 4Vote! Scientists uncover mechanism for melanoma drug resistance
- 4Vote! Study shows advance in using patients' own tumor-fighting cells to knock back advanced melanoma
- 9Vote! Vitamin A may slash melanoma risk
- 12Vote! Vitamin A May Slash Melanoma Risk, Especially in Women
(LiveScience.com)
Yahoo Science News - Thursday, 1 March
- 12Vote! Newly approved drug for metastatic melanoma nearly doubles median survival
- 7Vote! Smoking cessation drug improves walking function in patients with spinocerebellar ataxia type 3
PhysOrg - Wednesday, 22 February
- 7Vote! Study proves targeted tumor freezing therapy increases ovarian cancer survival
- 5Vote! A mile in their shoes: understanding empathy
